Tochikubo K, Isaka M, Yasuda Y, Kozuka S, Matano K, Miura Y, Taniguchi T
Department of Microbiology, Nagoya City University, Medical School, Japan.
Vaccine. 1998 Jan-Feb;16(2-3):150-5. doi: 10.1016/s0264-410x(97)00194-1.
We examined the mucosal adjuvant activity of recombinant cholera toxin B subunit (rCTB) produced by Bacillus brevis carrying pNU212-CTB by intranasal or oral co-administration of bovine serum albumin (BSA). Intranasal administration stimulated a high level of BSA-specific serum IgG antibody response and BSA-specific IgA antibody responses in the nasal and pulmonary lavages. Oral administration induced a moderate level of BSA-specific serum IgG antibody and a low level of BSA-specific IgA antibody in the large intestinal washes. These results show that CTB alone can act as an intranasal or oral delivery carrier; it also has strong adjuvant properties for stimulating serum IgG and mucosal IgA immune responses to unrelated, non-coupled antigens after intranasal or oral co-immunization.
我们通过鼻内或口服联合给予牛血清白蛋白(BSA),研究了携带pNU212-CTB的短短芽孢杆菌产生的重组霍乱毒素B亚单位(rCTB)的黏膜佐剂活性。鼻内给药刺激了高水平的BSA特异性血清IgG抗体反应以及鼻和肺灌洗液中的BSA特异性IgA抗体反应。口服给药在大肠灌洗液中诱导了中等水平的BSA特异性血清IgG抗体和低水平的BSA特异性IgA抗体。这些结果表明,单独的CTB可以作为鼻内或口服递送载体;在鼻内或口服联合免疫后,它还具有强大的佐剂特性,可刺激血清IgG和黏膜IgA对不相关、未偶联抗原的免疫反应。